Fusion Pharmaceuticals Inc. Forms 3, 4 and 5: Other
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 3 rows, 3 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-06-14: Reporting owner Duncan Barbara Gayle; Form 4; Security Stock Opion (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-14: Reporting owner Duncan Barbara Gayle; Form 4; Security Stock Opion (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-06-04: Reporting owner Duncan Barbara Gayle; Form 4; Security Stock Opion (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-06-14 | Duncan Barbara Gayle Director | 4 | Stock Opion (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,000 17,000 owned after | $4.64 exercise price | 2023-06-14 | |
| 2022-06-14 | Duncan Barbara Gayle Director | 4 | Stock Opion (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,000 17,000 owned after | $3.60 exercise price | 2022-06-22 | |
| 2021-06-04 | Duncan Barbara Gayle Director | 4 | Stock Opion (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,000 17,000 owned after | $8.15 exercise price | 2021-06-07 |